Dr Harsha Kariyawasam

Dr Harsha KariyawasamTel: 020 7915 1542
Fax: 020 7915 1674
Email: harsha.kariyawasam@nhs.net

Location:
Royal National Throat, Nose and Ear Hospital

Specialities:
Adult Severe Asthma Service, Ear, nose and throat services (ENT), Specialist Allergy and Clinical Immunology

Professional background

Dr. Harsha Kariyawasam is the Clinical Lead for Adult Allergy and Medical Rhinology at the Royal National Throat Nose Ear Hospital, London. He read medicine at St. Bartholomew’s Hospital Medical College, University of London. General medical training was undertaken in London, and specialist training in Allergy, Respiratory Medicine and Rhinology was completed at the Royal Brompton Hospital as Senior House Officer, Clinical Tutor and Specialist Registrar over a 7 year period. Further training at the Hammersmith Hospital (Airway Allergy and Disease), St Mary’s Hospital (General Allergy) and St Thomas Hospital (Skin Allergy) was also undertaken. He was awarded the PhD Thesis Prize in recognition of outstanding research performance in 2008 from the National Heart and Lung Institute, Imperial College London for work on how allergens injure the allergic airway and defining the growth factor molecular repair response to such injury. He undertook further post-doctoral research training in nasal allergy before taking up his Consultant post in 2008. He actively pursues clinical and basic science research related to general allergy, asthma, rhinitis, rhinology and immunotherapy. He is an honorary Senior Lecturer at both the MRC and Asthma UK centre in Allergic Mechanisms of Asthma and University College London.

  • Professional Membership
  • British Society for Allergy & Clinical Immunology
  • European Academy of Asthma, Allergy and Clinical Immunology
  • British Thoracic Society

Research interests

  1. Nasal polyps and Anti-IL-5 therapy
  2. Activin-A in severe asthma and mechanisms of immune regulation.
  3. Aspirin desentisation therapy in nasal polyps and asthma.
  4. Immune regulation mechanisms in chronic sinusitis and nasal polyps.
  5. Sublingual Immunotherapy (allergy desentisation) and effects on asthma.

Publications

Activin-A: a novel critical regulator of allergic asthma.
Kariyawasam HH, Semitekolou M, Robinson DS, Xanthou G.
Clin Exp Allergy. 2011 Nov;41(11):1505-14.
Chronic rhinosinusitis: therapeutic efficacy of anti-inflammatory and antibiotic approaches.
Kariyawasam HH, Scadding GK.
Allergy Asthma Immunol Res. 2011 Oct;3(4):226-35.
Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated.
Kariyawasam HH, Scadding GK.
J Asthma Allergy. 2010 Jun 21;3:19-28.
Developments in the field of allergy in 2008 through the eyes of Clinical & Experimental Allergy
Almqvist C, Bradding PB, Chakir J, Ebo D, Grattan C, Kariyawasam HH, Savilahti E, Scadding GK, Vieths S, Wardlaw AJ, Woodfolk J.
Clin Exp Allergy. 2009 Oct;39(10):1482-98.
Airways disease: just nosing around?
Scadding GK, Kariyawasam HH.
Thorax. 2009 Nov;64(11):923-5
Nicholson GC, Kariyawasam HH, Tan AJ, Hohlfeld JM, Quinn D, Walker C, Rodman D, 
Westwick J, Jurcevic S, Kon OM, Barnes PJ, Krug N, Hansel TT.
The effects of an anti-IL-13 monoclonal antibody on cytokine levels and nasal symptoms
following nasal allergen challenge.
J Allergy Clin Immunol. 2011 Oct;128(4):800-807.
Bonner K, Kariyawasam HH, Ali FR, Clark P, Kay AB
Expression of functional receptor activity modifying protein 1 by airway epithelial cells with  dysregulation in asthma
J Allergy Clin Immunol. 2010 Dec; 126(6):1277-83
Kariyawasam HH, Pegorier S, Barkans J, Xanthou G, Aizen M, Ying S, Kay AB, Lloyd
CM, Robinson DS.
Activin and transforming growth factor-beta signaling pathways are activated after allergen   challenge in mild asthma.
J Allergy Clin Immunol. 2009 Sep; 124(3):454-62.
Reynolds C, Barkans J, Clark P, Kariyawasam HH, Altmann D, Kay B, Boyton R.
Natural killer T cells in bronchial biopsies from human allergen challenge model of allergic
asthma
J Allergy Clin Immunol. 2009 Oct;124(4):860-2
Semitekolou M, Alissafi T, Aggelakopoulou M, Kourepini E, Kariyawasam HH,
Kay AB,  Robinson DS, Lloyd CM, Panoutsakopoulou V, Xanthou G.
Activin-A induces regulatory T cells that suppress T helper cell immune responses and    protect from allergic airway disease.
J Exp Med. 2009 Aug 3; 206(8):1769-85
Kariyawasam HH, Xanthou G, Barkans J, M.Aizen, Kay AB, Robinson DS
Basal expression of bone morphogenetic protein (BMP) receptor is reduced in asthma.
Am J Resp Crit Care Med, 2008 May 15; 177(10):1074-81.
Kariyawasam HH, Aizen M, Barkans J, Kay AB, Robinson DS
Safety and tolerability of three consecutive bronchoscopies in mild asthmatic volunteers after allergen challenge.
Thorax, 2007 Jun; 62(6):557-8.
Kariyawasam HH, Aizen M, Barkans J, Robinson DS, Kay AB
Remodeling and airway hyperresponsiveness but not cellular inflammation persists after allergen challenge in asthma.
Am J Respir Crit Care Med. 2007 May 1; 175(9): 896-904.
B.P. Madden, Kariyawasam HH, A.J. Siddiqi, A. Machin J.A. Pryor, M.E. Hodson
Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure.
Eur Respir J, 2002 Feb; 19(2):310-3.
Shori D, Genter T, Hansen J, Koch C, Wyatt H, Kariyawasam HH,  Knight R,. Hodson
M,Kalogeridis A, Tsanakas I
Altered sialyl- and fucosyl-linkage on mucins in cystic fibrosis patients promotes formation of the sialyl-Lewis X determinant on salivary MUC-5B and MUC-7.
Pflugers Arch. 2001; 443 Suppl 1:S55-61.
Shori D Kariyawasam HH, Knight R, Hodson M, Genter T, Hansen J, Koch C, A.
Kalogeridis A
Sulphation of the salivary mucin MG1 (MUC-5B) is not correlated to the degree of its sialylation and is unaffected by cystic fibrosis.
Pflugers Arch. 2001; 443 Suppl 1:S50-4.
Kariyawasam HH, Pepper JR, Hodson  ME, Geddes DM
Experience of totally implantable venous access devices (TIVADs) in adults with cystic fibrosis over a 13-year period.
Respir Med. 2000 Dec; 94(12):1161-5.
Kariyawasam HH, Gyi KM, Hodson ME, Cohen BJ
Anaemia in lung transplant patient caused by parvovirus B19.
Thorax. 2000 Jul; 55(7):619-20.

GMC/GDC number: 4108232